Urogen Announces Updated 18-Month Duration Of Response (Dor) Of 80.6% From The Phase 3 Envision Trial Of Ugn-102

Reuters
27 Apr
April 26 (Reuters) - Urogen Pharma Ltd ::
*UROGEN ANNOUNCES UPDATED 18-MONTH DURATION OF RESPONSE (DOR) OF 80.6% FROM THE PHASE 3 ENVISION TRIAL OF UGN-102, AN INVESTIGATIONAL TREATMENT FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (LG-IR-NMIBC)
*UROGEN PHARMA LTD - SUBMITS NDA TO FDA FOR UGN-102

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 26-APR-202522:30:00.083 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10